|本期目录/Table of Contents|

[1]孔菲,王研,吴昱华.比阿培南联合莫西沙星对重症肺炎患者疗效、炎性因子及血清CD40L、VACM-1的影响[J].中华肺部疾病杂志,2022,(04):533-535.[doi:10.3877/cma.j.issn.1674-6902.2022.04.021]
点击复制

比阿培南联合莫西沙星对重症肺炎患者疗效、炎性因子及血清CD40L、VACM-1的影响(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2022年04期
页码:
533-535
栏目:
临床研究
出版日期:
2022-08-20

文章信息/Info

Title:
-
作者:
孔菲1; 王研2; 吴昱华1
213300 常州,溧阳市人民医院药剂科1 210029 江苏,南京市胸科医院ICU2
Author(s):
-
关键词:
比阿培南;  莫西沙星;  重症肺炎;  临床疗效;  炎性因子;  CD40配体;  血管细胞黏附分子-1
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2022.04.021
摘要:
目的 分析比阿培南联合莫西沙星对重症肺炎患者疗效、炎性因子及血清CD40配体(CD40L)、血管细胞黏附分子-1(VACM-1)的影响。方法 选择2019年7月至2021年7月我院收治的57例重症肺炎为对象,依照治疗方法不同分为观察组30例与对照组27例。对照组接受比阿培南,观察组在对照组的基础联合受莫西沙星。对比两组治疗10 d后的疗效,血清超敏C反应蛋白(hs-CRP)、降钙素原(PCT)、氧合指数、动脉血氧分压(PaO2)、CD40L、VACM-1水平,对比10 d不良反应。结果 观察组总有效率(93.33%)较对照组(74.07%)高(P<0.05); 治疗10 d后,两组的血清hs-CRP、PCT水平降低(P<0.05),观察组较对照组低(P<0.05); 氧合指数、PaO2升高(P<0.05),观察组较对照组高(P<0.05); 血清CD40L、VACM-1水平低于治疗前(P<0.05),观察组较对照组低(P<0.05)。结论 比阿培南联合莫西沙星治疗重症肺炎疗效确切,可减轻机体炎症反应,改善免疫应答反应与血气指标。
Abstract:
-

参考文献/References:

1 Chahin A, Opal SM. Severe pneumonia caused by legionella pneumophila: Differential diagnosis and therapeutic considerations[J]. Infect Dis Clin North Am, 2017, 31(1): 111-121.
2 Simonovich VA, Burgos PL, Scibona P, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia[J]. N Engl J Med, 2021, 384(7): 619-629.
3 严锡祥, 郑爱东, 张振恩, 等. 重症肺炎患者肺复张治疗中不同体位对血流动力学的影响[J]. 医学临床研究, 2020, 17(11): 1647-1649, 1653.
4 Xie Y, Du J, Jin W, et al. Next generation sequencing for diagnosis of severe pneumonia: China, 2010-2018[J]. J Infect, 2019, 78(2): 158-169.
5 Chen HH, Shaw DM, Petty LE, et al. Host genetic effects in pneumonia[J]. Am J Hum Genet, 2021, 108(1): 194-201.
6 Cho JC, Zmarlicka MT, Shaeer KM, et al. Meropenem/vaborbactam, the first carbapenem/beta-Lactamase inhibitor combination[J]. Ann Pharmacother, 2018, 52(8): 769-779.
7 He L, He A, Qian Y. Imipenem-resistant pseudomonas aeruginosa treated with piperacillin/tazobactam in a patient with severe pneumonia: a case report and related literature review[J]. Ann Palliat Med, 2021, 10(1): 810-817.
8 Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: The LEAP 2 randomized clinical trial[J]. JAMA, 2019, 322(17): 1661-1671.
9 Li Y, Zhu D, Peng Y, et al. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia[J]. Curr Med Res Opin, 2021, 37(4): 693-701.
10 Meng X, Yang B, Suen WC. Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome[J]. Innate Immun, 2018, 24(1): 4-10.
11 Kunkler B, Salamango D, Debruine ZJ, et al. CUL5 is required for thalidomide-dependent inhibition of cellular proliferation[J]. PLoS One, 2018, 13(5): 196760.
12 陈 静, 孙 建, 冯晓丽, 等. 重症肺炎患者血清CD40L、VCAM-1、sTREM-1水平与病情和预后的关系[J]. 北华大学学报(自然科学版), 2020, 21(6): 775-778.
13 Venkataraman R, Gopichandran V, Ranganathan L, et al. Mortality prediction using acute physiology and chronic health evaluation Ⅱ and acute physiology and chronic health evaluation IV scoring systems: Is there a difference?[J]. Indian J Crit Care Med, 2018, 22(5): 332-335.
14 中华医学会呼吸病学分会感染学组. 中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J]. 中华结核和呼吸杂志, 2018, 41(4): 255-280.
15 李 娥, 吕佳杰. 莫西沙星与头孢哌酮钠舒巴坦钠治疗老年重症肺炎的联合疗效[J]. 西南国防医药, 2016, 26(3): 252-254.
16 徐元平, 杨 辉, 魏继红, 等. 重症肺炎临床特点及其并发抗生素相关性腹泻的临床分析[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(4): 472-474.
17 Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment[J]. J Investig Med, 2018, 66(6): 957-965.
18 Elabbadi A, Turpin M, Gerotziafas GT, et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia[J]. Infection, 2021, 49(3): 559-562.
19 Hang Y, Chen Y, Xue L, et al. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation[J]. Int J Antimicrob Agents, 2018, 51(3): 484-487.
20 王 薇, 田 蓉, 王 真, 等. 胸腺五肽辅助比阿培南对老年重症肺炎患者肺功能及血清SP-A及SP-D水平的影响[J]. 中国老年学杂志, 2020, 40(18): 3874-3877.
21 Sippola S, Haijanen J, Gronroos J, et al. Effect of oral moxifloxacin vs intravenous ertapenem plus oral levofloxacin for treatment of uncomplicated acute appendicitis: The APPAC Ⅱ randomized clinical Trial[J]. JAMA, 2021, 325(4): 353-362.
22 Naidoo A, Naidoo K, Mcilleron H, et al. A Review of moxifloxacin for the treatment of drug-susceptible tuberculosis[J]. J Clin Pharmacol, 2017, 57(11): 1369-1386.
23 薛世民, 蒋 伟, 贾 娟, 等. 莫西沙星治疗老年支原体肺炎患者的临床疗效分析[J]. 现代生物医学进展, 2016, 16(18): 3551-3554.
24 肖红雯, 彭 勇, 周洪伟, 等. 血必净注射液联合哌拉西林钠舒巴坦治疗老年重症肺炎的疗效及其对炎性因子和免疫功能的影响[J]. 中国老年学杂志, 2021, 41(19): 4218-4221.
25 周 瑜, 代艳梅, 王一平, 等. 老年重症肺炎患者细胞炎性因子、凝血功能情况及预后的影响因素分析[J]. 临床肺科杂志, 2020, 25(1): 70-73.
26 许利敏, 李 东, 李小燕, 等. 比阿培南不同滴注时间治疗重症肺炎的疗效与安全性比较[J]. 中国医院用药评价与分析, 2019, 19(6): 677-678, 682.
27 沈红卫, 麻建平. 老年重症肺炎与sICAM-1、IL-1R1、CD40L及TBX21基因多态性的相关性[J]. 中国老年学杂志, 2020, 40(13): 2781-2783.
28 沈晶晶, 刘建华, 曹 亮. 血清ApoA-I、CD40L、VCAM-1水平与老年SP患者SHG及预后相关性[J]. 分子诊断与治疗杂志, 2021, 13(4): 651-654.
29 胡大碧, 卢晓静, 况 刚, 等. 莫西沙星联合用药治疗老年重症肺炎疗效观察及对细菌清除率的影响[J]. 中国药业, 2018, 27(15): 64-66.
30 龚 敬, 陆 伟, 史 刚, 等. 比阿培南联合莫西沙星对老年重症肺炎患者炎性指标及不良反应的影响[J]. 河北医学, 2020, 26(5): 721-727.
31 Rosenthal IM, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?[J]. Am J Respir Crit Care Med, 2008, 178(9): 989-993.
32 Deshpande D, Srivastava S, Nuermberger E, et al. A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME Path on the Milky Way[J]. Clin Infect Dis, 2016, 63(suppl 3): S95-S101.

备注/Memo

备注/Memo:
基金项目: 江苏省自然科学基金面上项目(BK20191127)
通信作者: 孔 菲, Email: kf372384537@163.com
更新日期/Last Update: 2022-08-20